

Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Primary, Secondary), By Drug Type (Xanthine Oxidase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Competition

<https://marketpublishers.com/r/HC9ACB18CABBEN.html>

Date: October 2023

Pages: 180

Price: US\$ 4,900.00 (Single User License)

ID: HC9ACB18CABBEN

Abstracts

Global Hyperuricemia Market is anticipated to project robust growth in the forecast period. The Global Hyperuricemia Market is a dynamic and evolving sector within the healthcare industry that focuses on the diagnosis, treatment, and management of hyperuricemia, a condition characterized by elevated levels of uric acid in the blood. Hyperuricemia is primarily associated with gout, a painful form of arthritis, and is also linked to other medical conditions such as kidney stones and cardiovascular diseases. This market has witnessed significant growth in recent years, driven by several key factors. First and foremost, the rising prevalence of hyperuricemia worldwide has spurred demand for diagnostic tools and therapeutic options. Lifestyle changes, including unhealthy diets and sedentary lifestyles, have contributed to an increase in uric acid levels in many individuals. Additionally, the aging population is more susceptible to hyperuricemia, further fueling market growth.

The diagnostic segment of the global hyperuricemia market includes various tests and imaging techniques to measure uric acid levels and assess its impact on patients' health. These tools enable healthcare professionals to accurately diagnose

hyperuricemia and its associated conditions, allowing for timely intervention. In terms of therapeutics, pharmaceutical companies have developed a range of medications to manage hyperuricemia effectively. These drugs typically work by reducing uric acid production or enhancing its excretion, thus mitigating the risk of gout attacks and related complications. The market has witnessed the introduction of novel therapies, offering patients more options for personalized treatment. Furthermore, ongoing research and development efforts have led to the exploration of innovative treatment modalities such as gene therapy and precision medicine, potentially revolutionizing the hyperuricemia treatment landscape in the coming years.

Key Market Drivers

Increasing Prevalence of Hyperuricemia

The increasing prevalence of hyperuricemia is a pivotal driver behind the burgeoning Global Hyperuricemia Market. Hyperuricemia, characterized by elevated uric acid levels in the blood, has become increasingly common in recent years, marking a significant health concern worldwide. Lifestyle factors such as diets rich in purine-containing foods, sedentary habits, and the global rise in obesity rates have collectively contributed to this escalating health issue. Consequently, more individuals are finding themselves at risk of developing hyperuricemia, which is closely associated with painful conditions like gout, as well as kidney stones and cardiovascular diseases. This surge in hyperuricemia cases has created a substantial demand for diagnostic tools and therapeutic solutions, driving market growth. People are becoming more aware of the potential health risks associated with elevated uric acid levels, prompting them to seek medical attention and necessitating the need for accurate diagnostic tests. Healthcare professionals are increasingly diagnosing hyperuricemia in their patients, leading to early intervention and management, which in turn, propels the growth of the hyperuricemia market.

Moreover, the aging population is another significant factor contributing to the increased prevalence of hyperuricemia. Advanced age is a known risk factor for this condition, as the body's ability to process and excrete uric acid decreases with age. As the global population continues to age, a larger segment of society is becoming more susceptible to hyperuricemia, further intensifying the demand for diagnostic tests and treatment options.

Aging Population

The increasing aging population is a significant catalyst propelling the growth of the

Global Hyperuricemia Market. Hyperuricemia, characterized by elevated levels of uric acid in the bloodstream, becomes more prevalent with advancing age due to physiological changes in the body's ability to metabolize and excrete uric acid. As a result, the elderly demographic, defined by individuals aged 65 and above, is at a heightened risk of developing hyperuricemia and related conditions such as gout, kidney stones, and cardiovascular diseases. This demographic shift is occurring on a global scale, with many developed nations experiencing a surge in their elderly populations. Longer life expectancies and improved healthcare services have contributed to this phenomenon. With the elderly population growing steadily, there is a substantial increase in the number of individuals seeking medical attention for age-related health issues, including hyperuricemia.

The aging population's susceptibility to hyperuricemia has created a surge in demand for diagnostic tests and therapeutic interventions. Healthcare professionals are increasingly focusing on the early detection and management of hyperuricemia in older adults to mitigate the risk of gout attacks and associated complications. As a result, the hyperuricemia market has expanded its reach to cater to the specific needs of this aging demographic. Furthermore, the aging population's elevated prevalence of comorbidities, such as hypertension, diabetes, and obesity, often necessitates more aggressive management of hyperuricemia to prevent complications. This dynamic has led to the development of a range of therapeutic options, including medications that reduce uric acid levels, to address the unique healthcare challenges faced by the elderly population.

Diverse Therapeutic Options

Diverse therapeutic options are playing a pivotal role in driving the growth of the Global Hyperuricemia Market. Hyperuricemia, characterized by elevated uric acid levels in the blood, is a condition that has long been associated with painful disorders like gout, kidney stones, and cardiovascular diseases. The availability of a wide array of therapeutic interventions has significantly enhanced the management and treatment of hyperuricemia, contributing to the expansion of this market. Pharmaceutical companies have developed a diverse range of medications designed to tackle hyperuricemia through various mechanisms. These drugs work by either reducing the production of uric acid in the body or enhancing its excretion, effectively lowering uric acid levels. Established medications like allopurinol and febuxostat have been mainstays in hyperuricemia treatment, providing effective means to prevent gout attacks and related complications.

However, what truly boosts the hyperuricemia market is the continuous development of

novel therapeutic options. Emerging medications and therapies offer patients and healthcare providers more choices and flexibility in tailoring treatment plans. Some of these innovative treatments target specific pathways involved in uric acid metabolism, promising increased efficacy and fewer side effects. In addition to pharmaceutical interventions, lifestyle modifications and dietary changes also constitute a significant part of diverse therapeutic options. Patients are encouraged to make alterations to their diets, reducing the consumption of purine-rich foods and adopting healthier eating habits. Weight management and regular physical activity are also promoted as ways to manage hyperuricemia effectively, making lifestyle interventions an integral part of the comprehensive treatment approach. Furthermore, the advent of precision medicine and individualized treatment strategies has revolutionized the hyperuricemia market. Healthcare providers can now tailor treatment plans to the unique needs of each patient, taking into account their genetic makeup, comorbidities.

Key Market Challenges

Limited Routine Screening

For hyperuricemia, routine screening is particularly important because the condition often presents subtle or non-specific symptoms. Elevated uric acid levels can exist in the body for years without causing noticeable discomfort. However, over time, untreated hyperuricemia can lead to the development of gout, kidney stones, or cardiovascular diseases. Without routine screening, individuals with hyperuricemia may not become aware of their condition until they experience painful symptoms, such as gout attacks or kidney stones. This delay in diagnosis can result in more advanced disease stages and increased suffering. Routine screening offers a window of opportunity to educate individuals about their condition and recommend lifestyle modifications. For hyperuricemia, dietary changes, weight management, and increased physical activity can play a crucial role in managing uric acid levels. Without early detection, these opportunities are missed. Delayed diagnosis can lead to more extensive medical interventions and higher healthcare costs. Gout attacks, for example, often require urgent medical attention, potentially resulting in hospitalization. Routine screening, by contrast, is a cost-effective strategy for preventing such complications.

Ethical Concerns and Animal Welfare

Non-clinical trials, an essential phase in drug development and medical research, have encountered a significant hurdle in recent years – ethical concerns and animal welfare issues. These challenges, driven by growing awareness and ethical considerations,

have put pressure on the Global Hyperuricemia Market, influencing how trials are conducted and raising questions about the future of animal testing in biomedical research. One of the primary ethical concerns surrounding Hyperuricemia is the use of animals as test subjects. Many preclinical studies involve the testing of potential pharmaceuticals and medical devices on animals, including rodents, dogs, primates, and more. This practice has been crucial in evaluating the safety and efficacy of new treatments before they progress to human trials. However, it has sparked intense debates and activism from animal rights groups, which argue that animals should not bear the burden of experimentation.

Public opinion and ethical considerations have pushed regulatory agencies to impose stricter guidelines on the use of animals in research. For example, the '3Rs' principle – Replacement, Reduction, and Refinement – encourages researchers to explore alternative testing methods, reduce the number of animals used, and refine procedures to minimize suffering. While these principles are important steps toward more ethical research practices, they also introduce complexities and costs that can hinder the efficiency of non-clinical trials.

Key Market Trends

Research and Development

Research and Development (R&D) efforts have emerged as a crucial driving force behind the growth of the Global Hyperuricemia Market. Hyperuricemia, characterized by elevated levels of uric acid in the blood, is a condition intricately linked with debilitating ailments like gout, kidney stones, and cardiovascular diseases. In recent years, an increasing focus on R&D within the healthcare industry has spurred innovation and fostered advancements that are reshaping the landscape of hyperuricemia management. Pharmaceutical companies and academic institutions have intensified their exploration of novel treatment modalities and therapeutic approaches to address hyperuricemia comprehensively. Gene therapy, for instance, has emerged as a promising frontier in which researchers are investigating the possibility of directly modifying the genes responsible for uric acid metabolism. Such cutting-edge therapies hold the potential to revolutionize the treatment of hyperuricemia by providing patients with more effective and precisely targeted interventions.

Precision medicine is another significant area of R&D in the hyperuricemia market. This approach involves tailoring treatment plans to the unique genetic, biochemical, and lifestyle characteristics of individual patients. By understanding and leveraging these

individual factors, healthcare providers can develop highly personalized strategies for managing hyperuricemia. This not only enhances treatment efficacy but also minimizes potential side effects, leading to improved patient outcomes. Additionally, ongoing research efforts are shedding light on the intricate mechanisms of hyperuricemia and its links to various coexisting health conditions. This deeper understanding of the condition's complexities is facilitating the development of more precise diagnostic tools and innovative therapeutic options.

Varied Therapeutic Options

Hyperuricemia, characterized by elevated uric acid levels in the blood, is closely associated with debilitating conditions like gout, kidney stones, and cardiovascular diseases. The availability of a broad range of therapeutic interventions has substantially improved the management and treatment of hyperuricemia, contributing to the expansion of this market. Pharmaceutical companies have been at the forefront of developing diverse therapeutic options to effectively manage hyperuricemia. These medications work by either reducing uric acid production or enhancing its excretion, thus lowering uric acid levels in the bloodstream. Established drugs such as allopurinol and febuxostat have long been the mainstays of hyperuricemia treatment, providing effective means to prevent gout attacks and related complications.

However, what truly boosts the hyperuricemia market is the continuous development of novel therapeutic options. Emerging medications and therapies offer patients and healthcare providers more choices and flexibility in tailoring treatment plans. Some of these innovative treatments target specific pathways involved in uric acid metabolism, promising increased efficacy and fewer side effects. Moreover, lifestyle modifications and dietary changes also constitute a significant part of diverse therapeutic options for hyperuricemia. Patients are encouraged to make alterations to their diets, reducing the consumption of purine-rich foods, adopting healthier eating habits, and managing their weight. Regular physical activity is also promoted as an effective way to manage hyperuricemia. These lifestyle interventions, when combined with pharmaceutical treatments, provide a comprehensive approach to addressing hyperuricemia.

Segmental Insights

Drug Type Insights

Based on the Drug Type, the Xanthine Oxidase Inhibitors segment emerged as the dominant segment in the global market for Global Hyperuricemia Market in 2022.

Xanthine Oxidase Inhibitors, such as allopurinol and febuxostat, are specifically designed to lower uric acid levels by inhibiting the enzyme xanthine oxidase, which plays a crucial role in uric acid production. These medications have been shown to be highly effective in reducing serum uric acid levels, making them a preferred choice for long-term management of hyperuricemia.

Route of administration Insights

Based on the Route of Administration, the Oral administration segment emerged as the dominant player in the global market for Global Hyperuricemia Market in 2022. Oral medications are generally easier to administer compared to injectables. Patients can take oral medications by themselves without the need for healthcare professionals or specialized training. This convenience encourages better adherence to treatment plans.

Regional Insights

North America emerged as the dominant player in the global Hyperuricemia Market in 2022, holding the largest market share. This is due to several reasons as North America has witnessed a significant increase in the prevalence of hyperuricemia over the years. Lifestyle factors, including poor dietary habits, sedentary lifestyles, and increasing obesity rates, have contributed to the rising incidence of elevated uric acid levels.

Key Market Players

ArthroSi Therapeutics, Inc

Dr. Reddy's Laboratories Ltd.

Urica Therapeutics, Inc

Zydus Lifesciences

Takeda Pharmaceutical Company Limited

Novartis AG

Hikma Pharmaceuticals Plc

Mylan N.V.

AstraZeneca Plc

Sun Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Hyperuricemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Hyperuricemia Market, By Type:

Primary

Secondary

Global Hyperuricemia Market, By Drug Type:

Xanthine Oxidase Inhibitors

Nonsteroidal Anti-Inflammatory Drugs

Corticosteroids

Others

Global Hyperuricemia Market, By Route of Administration:

Oral

Injectable

Global Hyperuricemia Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Hyperuricemia Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Turkey

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hyperuricemia Market.

Available Customizations:

Global Hyperuricemia Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. GLOBAL HYPERURICEMIA MARKET OUTLOOK

- 4.1. Market Size & Forecast
 - 4.1.1. By Value
- 4.2. Market Share & Forecast
 - 4.2.1. By Type (Primary, Secondary)
 - 4.2.2. By Drug Type (Xanthine Oxidase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Others)
 - 4.2.3. By Route of Administration (Oral, Injectable)
 - 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

- 4.2.5. By Region
- 4.2.6. By Company (2022)
- 4.3. Market Map
 - 4.3.1. By Type
 - 4.3.2. By Drug Type
 - 4.3.3. By Route of Administration
 - 4.3.4. By Distribution Channel
 - 4.3.5. By Region

5. ASIA PACIFIC HYPERURICEMIA MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Type
 - 5.2.2. By Drug Type
 - 5.2.3. By Route of Administration
 - 5.2.4. By Distribution Channel
 - 5.2.5. By Country
- 5.3. Asia Pacific: Country Analysis
 - 5.3.1. China Hyperuricemia Market Outlook
 - 5.3.1.1. Market Size & Forecast
 - 5.3.1.1.1. By Value
 - 5.3.1.2. Market Share & Forecast
 - 5.3.1.2.1. By Type
 - 5.3.1.2.2. By Drug Type
 - 5.3.1.2.3. By Route of Administration
 - 5.3.1.2.4. By Distribution Channel
 - 5.3.2. India Hyperuricemia Market Outlook
 - 5.3.2.1. Market Size & Forecast
 - 5.3.2.1.1. By Value
 - 5.3.2.2. Market Share & Forecast
 - 5.3.2.2.1. By Type
 - 5.3.2.2.2. By Drug Type
 - 5.3.2.2.3. By Route of Administration
 - 5.3.2.2.4. By Distribution Channel
 - 5.3.3. Australia Hyperuricemia Market Outlook
 - 5.3.3.1. Market Size & Forecast
 - 5.3.3.1.1. By Value

- 5.3.3.2. Market Share & Forecast
 - 5.3.3.2.1. By Type
 - 5.3.3.2.2. By Drug Type
 - 5.3.3.2.3. By Route of Administration
 - 5.3.3.2.4. By Distribution Channel
- 5.3.4. Japan Hyperuricemia Market Outlook
 - 5.3.4.1. Market Size & Forecast
 - 5.3.4.1.1. By Value
 - 5.3.4.2. Market Share & Forecast
 - 5.3.4.2.1. By Type
 - 5.3.4.2.2. By Drug Type
 - 5.3.4.2.3. By Route of Administration
 - 5.3.4.2.4. By Distribution Channel
- 5.3.5. South Korea Hyperuricemia Market Outlook
 - 5.3.5.1. Market Size & Forecast
 - 5.3.5.1.1. By Value
 - 5.3.5.2. Market Share & Forecast
 - 5.3.5.2.1. By Type
 - 5.3.5.2.2. By Drug Type
 - 5.3.5.2.3. By Route of Administration
 - 5.3.5.2.4. By Distribution Channel

6. EUROPE HYPERURICEMIA MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Type
 - 6.2.2. By Drug Type
 - 6.2.3. By Route of Administration
 - 6.2.4. By Distribution Channel
 - 6.2.5. By Country
- 6.3. Europe: Country Analysis
 - 6.3.1. France Hyperuricemia Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Type
 - 6.3.1.2.2. By Drug Type

- 6.3.1.2.3. By Route of Administration
- 6.3.1.2.4. By Distribution Channel
- 6.3.2. Germany Hyperuricemia Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Type
 - 6.3.2.2.2. By Drug Type
 - 6.3.2.2.3. By Route of Administration
 - 6.3.2.2.4. By Distribution Channel
- 6.3.3. Spain Hyperuricemia Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Type
 - 6.3.3.2.2. By Drug Type
 - 6.3.3.2.3. By Route of Administration
 - 6.3.3.2.4. By Distribution Channel
- 6.3.4. Italy Hyperuricemia Market Outlook
 - 6.3.4.1. Market Size & Forecast
 - 6.3.4.1.1. By Value
 - 6.3.4.2. Market Share & Forecast
 - 6.3.4.2.1. By Type
 - 6.3.4.2.2. By Drug Type
 - 6.3.4.2.3. By Route of Administration
 - 6.3.4.2.4. By Distribution Channel
- 6.3.5. United Kingdom Hyperuricemia Market Outlook
 - 6.3.5.1. Market Size & Forecast
 - 6.3.5.1.1. By Value
 - 6.3.5.2. Market Share & Forecast
 - 6.3.5.2.1. By Type
 - 6.3.5.2.2. By Drug Type
 - 6.3.5.2.3. By Route of Administration
 - 6.3.5.2.4. By Distribution Channel

7. NORTH AMERICA HYPERURICEMIA MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Drug Type

7.2.2. Type

7.2.3. By Distribution Channel

7.2.4. By Route of Administration

7.2.5. By Country

7.3. North America: Country Analysis

7.3.1. United States Hyperuricemia Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By Drug Type

7.3.1.2.3. By Route of Administration

7.3.1.2.4. By Distribution Channel

7.3.2. Mexico Hyperuricemia Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

7.3.2.2.2. By Drug Type

7.3.2.2.3. By Route of Administration

7.3.2.2.4. By Distribution Channel

7.3.3. Canada Hyperuricemia Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By Drug Type

7.3.3.2.3. By Route of Administration

7.3.3.2.4. By Distribution Channel

8. SOUTH AMERICA HYPERURICEMIA MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type

8.2.2. By Drug Type

- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. South America: Country Analysis
 - 8.3.1. Brazil Hyperuricemia Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Type
 - 8.3.1.2.2. By Drug Type
 - 8.3.1.2.3. By Route of Administration
 - 8.3.1.2.4. By Distribution Channel
 - 8.3.2. Argentina Hyperuricemia Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Type
 - 8.3.2.2.2. By Drug Type
 - 8.3.2.2.3. By Route of Administration
 - 8.3.2.2.4. By Distribution Channel
 - 8.3.3. Colombia Hyperuricemia Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Type
 - 8.3.3.2.2. By Drug Type
 - 8.3.3.2.3. By Route of Administration
 - 8.3.3.2.4. By Distribution Channel

9. MIDDLE EAST AND AFRICA HYPERURICEMIA MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Type
 - 9.2.2. By Drug Type
 - 9.2.3. By Route of Administration
 - 9.2.4. By Distribution Channel
 - 9.2.5. By Country
- 9.3. MEA: Country Analysis

9.3.1. South Africa Hyperuricemia Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type

9.3.1.2.2. By Drug Type

9.3.1.2.3. By Route of Administration

9.3.1.2.4. By Distribution Channel

9.3.2. Saudi Arabia Hyperuricemia Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type

9.3.2.2.2. By Drug Type

9.3.2.2.3. By Route of Administration

9.3.2.2.4. By Distribution Channel

9.3.3. UAE Hyperuricemia Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type

9.3.3.2.2. By Drug Type

9.3.3.2.3. By Route of Administration

9.3.3.2.4. By Distribution Channel

9.3.4. Egypt Hyperuricemia Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Type

9.3.4.2.2. By Drug Type

9.3.4.2.3. By Route of Administration

9.3.4.2.4. By Distribution Channel

10. MARKET DYNAMICS

10.1. Drivers

10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

- 11.1. Recent Developments
- 11.2. Product Launches
- 11.3. Mergers & Acquisitions

12. GLOBAL HYPERURICEMIA MARKET: SWOT ANALYSIS

13. PORTER'S FIVE FORCES ANALYSIS

- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Product

14. COMPETITIVE LANDSCAPE

- 14.1. ArthroSi Therapeutics, Inc
 - 14.1.1. Business Overview
 - 14.1.2. Company Snapshot
 - 14.1.3. Products & Services
 - 14.1.4. Current Capacity Analysis
 - 14.1.5. Financials (In case of listed)
 - 14.1.6. Recent Developments
 - 14.1.7. SWOT Analysis
- 14.2. Dr. Reddy's Laboratories Ltd.
- 14.3. Urica Therapeutics, Inc
- 14.4. Zydus Lifesciences
- 14.5. Takeda Pharmaceutical Company Limited
- 14.6. Novartis AG
- 14.7. Hikma Pharmaceuticals Plc
- 14.8. Mylan N.V.
- 14.9. AstraZeneca Plc
- 14.10. Sun Pharmaceutical Industries Ltd

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Primary, Secondary), By Drug Type (Xanthine Oxidase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Competition

Product link: <https://marketpublishers.com/r/HC9ACB18CABBEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HC9ACB18CABBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970